Insider trade

Inmune Bio (INMB): Chief Scientific Officer exercised options on 7,211 units

Mark William Lowdell, Chief Scientific Officer at Inmune Bio, reported an option exercise of 7,211 units.

7,211
Derivative units · @ $0.125
Traded
Jul 2, 2026
Filed
Jul 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 29, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  2. Jun 16, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As noted in Item 5.07 below, on June 16, 2026, INmune Bio Inc. (the “Company”), held its annual meeting of stockholders (the “Annual Meeting”), where the stockholders of the Company approved the Company’s Third Amended and Restated 2021 Stock Incentive Plan (the “Amended Plan”), pursuant to which the shares of the Company’s common stock issuable under the Company’s Amended and Restated 2021 Stock Incentive Plan was…”
  3. Jun 30, 2026Company filing · Form 8-K · Material agreementSigned an important agreement

What came next

  1. Sep 8, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On September 8, 2026, the Board of Directors (the “Board”) of INmune Bio, Inc. (the “Company”) approved to increase the number of directors and to set the number of directors serving on the Board at seven, and, pursuant to the Company’s by-Laws, appointed R. Duane Clark II and James Sapirstein to serve as directors of the Company until the next annual election and until their successors are duly elected and…”
  2. Oct 27, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Inmune Bio

For Inmune Bio, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its INMB page.

How this filing works

Explore the data

Common questions

Which Inmune Bio (INMB) insider traded, and how much?

Mark William Lowdell, Chief Scientific Officer at Inmune Bio, reported an option exercise of 7,211 units. At $0.13.

When did it happen, and when was it made public?

Traded: Jul 2, 2026. Filed: Jul 7, 2026. That is 5 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Inmune Bio recently?

For Inmune Bio, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the INMB page.

Does this mean INMB stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Inmune Bio

Everything OQRO holds on this company is on its INMB page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data